Dementia and mild cognitive impairment in Parkinson's disease

Fonseca, Lineu Corrêa; Letro, Grace Helena; Bossoni, Alexandre Souza; Bastos, Samara Adriana

doi:10.1590/s0004-282x2009000600038

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A ocorrência de demência na DP é comum e sua prevalência aumenta com o tempo de doença, variando de 23% nos primeiros anos da doença a 80% com mais de 15 anos de sintomas [15][16][17] . O conhecimento de quais fatores de risco estão associados à ocorrência de demência em pacientes com DP e as características que diferenciam os pacientes com DCL de outras etiologias são essenciais para um diagnóstico precoce e uma terapia mais adequada.…”

Section: Epidemiologiaunclassified

Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

Parmera

Tumas

Ferraz

et al. 2022

Dement. neuropsychol.

View full text Add to dashboard Cite

RESUMO A demência da doença de Parkinson (DDP) e a demência com corpos de Lewy (DCL) representam a segunda causa mais comum de demência neurodegenerativa em pessoas com mais de 65 anos, ocasionando progressivo declínio cognitivo e comprometimento da qualidade de vida. O presente estudo tem como objetivo prover um consenso de especialistas sobre a DDP e DCL, baseado em revisão sistemática da literatura brasileira e revisão não-sistemática de literatura internacional. Ademais, tal estudo visa promover informação e conceder recomendações sobre abordagem diagnóstica, com foco nos níveis de atenção primária e secundária em saúde. Com base nos dados disponíveis, recomendamos que os profissionais realizem pelo menos um breve instrumento cognitivo global, como o Mini-Exame do Estado Mental, contudo de preferência optem pela Avaliação Cognitiva de Montreal e o Exame Cognitivo de Addenbrooke-Revisado. Observa-se uma carência de instrumentos validados para a avaliação precisa das habilidades funcionais em pacientes brasileiros com DDP e DCL. Além disso, mais estudos focando em biomarcadores com coortes brasileiras também são necessários.

show abstract

Section: Epidemiologiaunclassified

Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

Parmera

Tumas

Ferraz

et al. 2022

Dement. neuropsychol.

View full text Add to dashboard Cite

show abstract

“…Dementia frequently occurs in PD and its prevalence increases with disease duration, ranging from 23% in the first years of the disease to 80% after over 15 years of symptoms [15][16][17] . Understanding which risk factors are associated with the occurrence of dementia in PD patients and what differentiates LBD patients from other etiologies is essential for an earlier diagnosis and more appropriate therapy for the disease.…”

Section: Epidemiologymentioning

confidence: 99%

Diagnosis and management of Parkinson’s disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Parmera

Tumas

Ferraz

et al. 2022

Dement. neuropsychol.

View full text Add to dashboard Cite

Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) represent the second most common type of degenerative dementia in patients aged 65 years and older, leading to progressive cognitive dysfunction and impaired quality of life. This study aims to provide a consensus based on a systematic Brazilian literature review and a comprehensive international review concerning PDD and DLB. Moreover, we sought to report on and give recommendations about the best diagnostic approaches focusing on primary and secondary care. Based on the available data, we recommend clinicians to apply at least one brief global cognitive instrument to assess PDD, such as the Mini-Mental State Examination and preferably the Montreal Cognitive Assessment and the Addenbrooke’s Cognitive Examination-Revised. Validated instruments to accurately assess functional abilities in Brazilian PD patients are still incipient. Further studies should focus on biomarkers with Brazilian cohorts.

show abstract

Section: Introductionmentioning

confidence: 99%

“…6 Despite being referred to as a single and nonamnestic domain, the criteria for this diagnosis are not well established in the literature, with controversies regarding the definition and characteristics of mild cognitive impairment in PD (MCI-PD), due to the methodological diversity among studies. [6][7][8] Dementia in Parkinson's disease (D-PD) is the most serious manifestation. This condition affects $ 24 to 31% of patients, increases death risk, and leads to a reduction in the quality of life of patients and caregivers, besides causing an increase in institutionalization and in costs.…”

Section: Introductionmentioning

confidence: 99%

Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease

Sousa

Brucki

2023

Arq Neuropsiquiatr

View full text Add to dashboard Cite

Background Cognitive deficit in Parkinson disease (PD) is an important cause of functional disability in these patients and early detection, with sensitive instruments, can contribute to longitudinal monitoring. Objective To investigate the diagnostic accuracy, sensitivity, and specificity of the Addenbrooke's Cognitive Examination-III in patients with PD, using the comprehensive neuropsychological battery as reference method. Methods Cross-sectional, observational, case-control study. Setting: rehabilitation service. A total of 150 patients and 60 healthy controls matched for age, sex, and education. For level I assessment, Addenbrooke Cognitive Examination (ACE-III) was used. Level II assessment used a comprehensive neuropsychological battery of standardized tests for this population. All patients remained in on-state during the study. The diagnostic accuracy of the battery was investigated through the receiver operating characteristic (ROC) analysis. Results The clinical group was divided into 3 subgroups: normal cognition in Parkinson's disease (NC-PD-16%), mild cognitive impairment due to Parkinson's disease (MCI-PD-69.33%), and dementia due to Parkinson's disease (D-PD-14.66%). ACE-III optimal cutoff scores for detecting MCI-PD and D-PD were 85/100 (sensitivity 58.65%, specificity 60%) and 81/100 points (sensitivity 77.27%, specificity 78.33%), respectively. Age was inversely associated with the performance of the scores (totals and domains of the ACE-III), while the level of education had a significantly positive correlation in the performance of these scores. Conclusions ACE-III is a useful battery for assessing the cognitive domains and to differentiate individuals with MCI-PD and D-PD from healthy controls. Future research, in a community setting, is necessary to provide discriminatory capacity of ACE-III in the different severities of dementia.

show abstract

Dementia and mild cognitive impairment in Parkinson's disease

Cited by 3 publications

References 10 publications

Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

Diagnóstico e manejo da demência da doença de Parkinson e demência com corpos de Lewy: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

Diagnosis and management of Parkinson’s disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease

Contact Info

Product

Resources

About